Metastatic hormone sensitive prostate cancer research hub
9 indexed studies · 5 currently recruiting
- recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)
This study is looking at a new treatment for men with prostate cancer that has spread and still responds to hormone therapy. It compares a new drug, pembrolizumab, with a standard treatment (enzalutamide and hormone therapy) to see if it works better at slowing cancer growth and helping men live longer.
Denmark · Poland · Ireland - recruiting
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
This study looks at how men with advanced prostate cancer respond to darolutamide and hormone therapy, sometimes with chemotherapy, in real-world settings. It aims to understand treatment effectiveness, safety, and patient experiences to help improve care.
Belgium · Finland · France - recruiting
A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
This study looks at how well men with a certain type of prostate cancer (metastatic hormone-sensitive prostate cancer) stick to their apalutamide medication in France. It wants to understand why some men might not take their medicine as prescribed.
France - recruitingPHASE2
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
This study looks at a new drug, JSB462, with existing treatments (abiraterone or enzalutamide) for men with advanced prostate cancer that is still sensitive to hormone therapy. It aims to find the best dose and check how well it works and if it's safe.
United States · Australia · Brazil - active not recruiting
An Observational Study to Learn More About Treatment Patterns and Factors Determining the Choice of Treatment in Canadian Men With Metastatic Hormone Sensitive Prostate Cancer in Routine Medical Care
This study looks at how Canadian men with prostate cancer that has spread, and still responds to hormone treatment, are cared for in real life. Researchers collect information from patient records to understand treatment choices and patterns, without changing anyone's care.
Canada - authorisedTherapeutic confirmatory (Phase III)
Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2)
This study, called STAMPEDE2, is looking at new treatments for men with prostate cancer that has spread. It compares different treatments, including a drug called Pluvicto, to see if they help men live longer and have a better quality of life.
Ireland · Germany · Spain - active not recruiting
A Study for the Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated With Androgen Deprivation Therapy (ADT) Plus Apalutamide or Enzalutamide
This study looks at real-world results for men with prostate cancer that has spread and is sensitive to hormones. It compares two medicines, apalutamide and enzalutamide, which are given alongside standard hormone therapy to see how well they work.
Austria · France · Germany - recruitingPHASE2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
This study looks at a new injection, ASP5541, for advanced prostate cancer that has spread. It compares ASP5541 to a standard tablet treatment, abiraterone acetate, to see how safe and effective it is.
United States · China · France - authorisedTherapeutic confirmatory (Phase III)
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
This study looks at a new way to treat prostate cancer that has spread. It combines existing treatments to see if it can keep the cancer from getting worse for longer. It focuses on men whose cancer didn't respond enough to the first treatment.
Spain · Germany · France